[Form 4] Amtech Systems Inc Insider Trading Activity
Robert C. Daigle, Chairman & CEO and a director of Amtech Systems, Inc. (ASYS), was granted an employee stock option for 100,000 shares. The option has an exercise price of $5.09, is dated 08/08/2025, becomes exercisable on 08/08/2026 and expires on 08/08/2030, and it covers 100,000 underlying shares of Amtech common stock held directly.
The Form 4 reports this option grant as an acquisition (A) of a derivative security; the filing notes the price field is omitted because this is a grant. No other transactions or changes in ownership are reported on this form.
- Long-term alignment: Grant vests by 08/08/2026 and expires 08/08/2030, aligning CEO incentives with multi-year performance
- Transparency: Transaction and material terms (exercise price, exercisable date, expiration, and quantity) are disclosed on Form 4
- Potential dilution: Full exercise would add 100,000 common shares, increasing outstanding share count
- Missing vesting detail: The filing does not specify vesting schedule or performance conditions, limiting assessment of incentive design
Insights
TL;DR: A CEO option grant of 100,000 shares is a routine executive compensation action with governance and dilution implications investors should note.
The grant to the CEO aligns compensation with long-term equity performance given a multi-year vest/exercise window. It creates potential future dilution of 100,000 shares if fully exercised, and the $5.09 exercise price establishes the financial hurdle for value capture. This filing does not disclose vesting schedule details beyond the exercisable start and expiration dates, so the immediate governance impact is limited to observable dilution and incentive alignment.
TL;DR: The option grant is a standard long-term incentive; materiality depends on company share count and existing equity program size, not disclosed here.
From a pay-design perspective, a 100,000-share option at $5.09 suggests a significant award for the CEO but the form lacks information on vesting criteria, performance conditions, or whether this is part of an annual grant program. Without total outstanding shares or prior grants disclosed here, we cannot quantify dilution percentage or relative grant size.